相关实验视频

Updated: Feb 19, 2026

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis

Analyzing Beneficial Effects of Nutritional Supplements on Intestinal Epithelial Barrier Functions During Experimental Colitis

Published on: January 5, 2017

沃克洛斯波林在实验性大肠炎中显示出保护作用和肠道屏障强制执行

M Gabel¹, A Knauss¹, Y Liu¹

¹Department of Medicine 1, University Hospital Erlangen, Erlangen, Germany.

Frontiers in medicine

|February 18, 2026

概括

沃克洛斯波林和环素A显示出治疗炎症性肠病 (IBD) 的潜力. 这两种药物都减少了肠道炎症,并在临床前模型中抑制了关键的炎症触发因素.

科学领域:

胃肠病学胃肠病学
免疫学免疫学免疫学
药理学药理学是指药理学的学科.

背景情况:

炎症性肠病 (IBD) 存在重大治疗挑战.
对相关疾病的既定药物可能为IBD提供新的治疗途径.
已被批准用于狼性炎的Voclosporin是IBD治疗的潜在候选药物.

研究的目的:

在实验性结肠炎模型中评估Voclosporin的疗效和机制.
为了比较Voclosporin与环素A (CsA) 的作用.
调查Voclosporin对肠道屏障功能和炎症通路的影响.

主要方法:

在小鼠和人类外周血液单核细胞 (PBMC) 中实验性结肠炎模型.
使用迷你内镜,组织病理学和多光子内显微镜 (MPEM) 评估炎症.
通过免疫光,流细胞计和细胞因子分析分析细胞反应.

主要成果:

沃克洛斯波林和CsA都改善了结肠炎相关的体重减轻,并减少了肠道炎症.
沃克洛斯波林显著增加了结肠克劳丁3的表达,这是一种加强肠道屏障的蛋白质.
沃克洛斯波林和CsA抑制了在人类PBMC中IL2诱导型氨酸激酶 (ITK) 的激活.

结论:

沃克洛斯波林在急性肠道炎症中显示出治疗潜力.
该药物增强了肠道屏障功能,并抑制了关键的炎症媒介.
沃克洛斯波林是治疗炎症性肠病的一个有前途的策略.

关键词:

IBD IBD IBD IBD IBD IBD IBD IBD IBD IBD IBD IBD IBD IBD IBD 在Voclosporin中使用.卡尔西纽林抑制剂卡尔西纽林抑制剂实验性结肠炎是什么治疗治疗治疗治疗治疗治疗

更多相关视频

Investigating Intestinal Barrier Breakdown in Living Organoids

Investigating Intestinal Barrier Breakdown in Living Organoids

Published on: March 26, 2020

Author Spotlight: Studying the Epithelial Effects of Intestinal Inflammation In Vitro on Established Murine Colonoids

Author Spotlight: Studying the Epithelial Effects of Intestinal Inflammation In Vitro on Established Murine Colonoids

Published on: June 2, 2023

相关概念视频

Drugs for Treatment of Ulcerative Colitis in IBD

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...

Bioavailability Enhancement: Drug Stability Enhancement and GI Retention

Bioavailability Enhancement: Drug Stability Enhancement and GI Retention

Body:Improving a drug's stability in the gastrointestinal (GI) tract is paramount for enhancing its bioavailability and therapeutic effectiveness. Various strategies are employed to protect the drug from the harsh gastric milieu and to ensure its release and absorption at the desired site within the GI tract.Polymer coatings are one such method used to shield drugs from the stomach's acidic environment. By preventing premature drug release, these coatings improve the bioavailability of unstable...

Inflammatory Bowel Disease IV: Pharmacological Management

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...

Mucosal Barrier of the Stomach

Mucosal Barrier of the Stomach

The gastric glands contain parietal cells that secrete hydrochloric acid (HCl) for digestion. The cells secrete HCl because it is highly corrosive and essential for breaking down food. To achieve this, they secrete hydrogen and chloride ions into the lumen of the gastric glands, which combine to form HCl.
Within parietal cells, carbonic acid is first formed through the reaction of water and carbon dioxide. The dissociation of carbonic acid releases bicarbonate and hydrogen ions. The bicarbonate...

Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents

Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents

In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...